Improving Outcomes and Addressing Racial Disparities in Patients With HR+/HER2- Early Breast Cancer: A Case-Based Learning Lab 30.04.2024 21:00

Host: Sara M. Tolaney, MD, MPH The emergence of the cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has transformed the treatment landscape for patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) metastatic breast cancer, with emerging evidence supporting their utility in the early breast cancer (eBC) setting in combination with adjuvant endocrine...

Expert Answers to Common Questions on Response Matters: Transforming the Standard of Care in CML by Mastering Response-Guided Treatment 13.02.2024 13:00

Guest: Michael J. Mauro, MD Chronic myeloid leukemia is a myeloproliferative neoplasm characterized by disordered growth of myeloid cells. The hallmark of chronic myeloid leukemia (CML) is an acquired reciprocal translocation between the long arms of chromosomes 9 and 22. This translocation results in the BCR-ABL1 fusion protein, with constitutively active tyrosine kinase activity, and is the unde...

Expert Answers to Common Questions on Response Matters: Transforming the Standard of Care in CML by Mastering Response-Guided Treatment 13.02.2024 13:00

Guest: Michael J. Mauro, MD Chronic myeloid leukemia is a myeloproliferative neoplasm characterized by disordered growth of myeloid cells. The hallmark of chronic myeloid leukemia (CML) is an acquired reciprocal translocation between the long arms of chromosomes 9 and 22. This translocation results in the BCR-ABL1 fusion protein, with constitutively active tyrosine kinase activity, and is the unde...

Chairperson’s Perspective: CDK 4/6 Inhibitors: Practice-Changing Implications of Targeted Therapies in HR+/HER2- Breast Cancer 31.12.2023 31:30

Guest: Joyce O'Shaughnessy, MD By 2040, the global breast cancer burden is expected to increase by 40%, resulting in more than 3 million new cases and 1 million deaths per year. Approximately 65% of cases among women less than 50 years of age and 75% of cases among women over 50 years of age are classified as HR+/HER2-. Although endocrine therapy is employed as standard-of-care treatment for...

Chairperson’s Perspective: CDK 4/6 Inhibitors: Practice-Changing Implications of Targeted Therapies in HR+/HER2- Breast Cancer 31.12.2023 31:30

Guest: Joyce O'Shaughnessy, MD By 2040, the global breast cancer burden is expected to increase by 40%, resulting in more than 3 million new cases and 1 million deaths per year. Approximately 65% of cases among women less than 50 years of age and 75% of cases among women over 50 years of age are classified as HR+/HER2-. Although endocrine therapy is employed as standard-of-care treatment for...

Should We Look for Gout in the Cardiology Clinic? 24.10.2023 4:00

Host: Richard Johnson, MD Guest: Brittany Weber, MD, PhD This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney dise...

What Are the Emerging Therapies for Managing Gout? 24.10.2023 5:00

Host: Richard Johnson, MD Guest: John K. Botson, MD, RPh This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney dise...

What’s New About Gout? Rheumatology Perspective 24.10.2023 5:00

Host: Richard Johnson, MD Guest: John K. Botson, MD, RPh This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney dise...

What’s New About Gout? Nephrology Perspective 24.10.2023 5:00

Host: Abdul Abdellatif, MD, FASN Guest: Richard Johnson, MD This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney d...

Can You Manage Patients With Uncontrolled Gout More Effectively? 24.10.2023 5:00

Host: Abdul Abdellatif, MD, FASN Guest: John K. Botson, MD, RPh This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidn...

Treat or Refer: Who Is Responsible for Managing Gout? 24.10.2023 5:00

Host: John K. Botson, MD, RPh Guest: Abdul Abdellatif, MD, FASN This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidn...

Center of the Target: Which Patients Are Most Likely to Develop Gout? 24.10.2023 5:00

Host: Richard Johnson, MD Guest: Abdul Abdellatif, MD, FASN This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney d...

Is Managing Gout in the Nephrology Clinic a Challenge? 24.10.2023 4:30

Host: Richard Johnson, MD Guest: Abdul Abdellatif, MD, FASN This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney d...

Is Gout Hiding in the Nephrology Clinic? 24.10.2023 5:00

Host: Abdul Abdellatif, MD, FASN Guest: Richard Johnson, MD This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney d...

Gout Beyond the Joints: What’s the Hidden Danger? 24.10.2023 3:30

Host: Richard Johnson, MD This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and...